Frontotemporal dementia (FTD) is an insidious neurodegenerative clinical syndrome characterized by progressive deficits in behavior, executive function, and language, with a specific involvement of the frontal and temporal regions of the brain. It is a common type of dementia, particularly in patients younger than 65 years. Albeit there is an urgent need to find therapeutic regimens that can deal, at least partially, with FTD symptoms, currently no approved disease-modifying drugs are available to treat FTD, nor even to slow the progression of symptoms. Recently, it has been hypothesized that an impairment of dopaminergic neurotransmission could be implicated in FTD, specifically in the behavioral variant of FTD (bv-FTD). Although experimental evidence supports the use of drugs increasing dopaminergic neurotransmission in treating FTD, this hypothesis has not been fully explored in a clinical trial. We have recently demonstrated that dopaminergic drugs treatment can be effective in improving executive functions in mild Alzheimer’s disease patients, with a specific increase of frontal brain activity.  Starting from this knowledge, we will test the safety and efficacy of Rotigotine, a dopaminergic agonist, in bv-FTD patients. Additionally, we will perform neurophysiological and neuroimaging investigations that will allow us to explore the neural correlates underlying the effects induced by our proposed intervention. Potentially the proposed project could deepen our understanding of the pathophysiology of neurotransmitters dysfunction involved in FTD and hopefully could provide a valid treatment for cognitive dysfunctions in FTD patients.